Related Experiment Video
Updated: Mar 16, 2026
08:35
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
3.4K
Extracorporeal Life Support in Multisystem Smooth Muscle Dysfunction Syndrome
Sudesh Prabhu1,2,3, Scott Fox1, Adrian Mattke1,2,3,4
11 Queensland Paediatric Cardiac Services, Lady Cilento Children's Hospital, Brisbane, Queensland, Australia.
World Journal for Pediatric & Congenital Heart Surgery
|August 24, 2016
Summary
This study details an infant with multisystemic smooth muscle dysfunction syndrome, characterized by congenital mydriasis, patent ductus arteriosus, and cystic lung disease. The infant
Area of Science:
- Genetics
- Pediatrics
- Cardiology
Background:
- Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare genetic disorder affecting multiple organs.
- Early diagnosis and intervention are crucial for managing severe pediatric cases.
Observation:
- An infant presented with congenital mydriasis, patent ductus arteriosus (PDA), pulmonary hypertension, and cystic lung disease.
- The patient exhibited major components consistent with multisystemic smooth muscle dysfunction syndrome.
Findings:
- Genetic testing confirmed an ACTA2 R179H mutation, the causative agent of MSMDS.
- Lung biopsy revealed cystic lung disease, a significant finding in this case.
Implications:
- This case highlights the critical role of genetic testing in diagnosing MSMDS.
- Aggressive respiratory support and surgical intervention (PDA interruption, ECMO) were necessary due to disease severity.
- Understanding ACTA2 mutations is vital for developing targeted therapies for smooth muscle disorders.
